Evommune, Inc. (NYSE: EVMN)

Sector: Healthcare Industry: Biotechnology CIK: 0002044725
P/B -1.26
P/E -3.39
P/S 33.04
Market Cap 231.25 Mn
ROIC (Qtr) 0.00
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 160,000.00
Debt/Equity (Qtr) 0.00

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 28.23M provide 176.44x coverage of short-term debt 160000, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 84.54M provides 528.40x coverage of total debt 160000, indicating robust asset backing and low credit risk.
  • Short-term investments of 49.24M provide solid 7.37x coverage of other current liabilities 6.68M, indicating strong liquidity.
  • Retained earnings of (192.82M) represent substantial 1.05x of equity (183.14M), indicating strong internal capital generation.
  • Tangible assets of 84.54M provide robust 12.66x coverage of other current liabilities 6.68M, indicating strong asset backing.

Cons

  • Tangible assets of 84.54M provide limited backing for working capital of 71.53M, which is 1.18x, suggesting increased operational risk in market downturns.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 0.00 12.31
EV to Cash from Ops. 0.00 23.25
EV to Debt 0.00 738.44
EV to EBIT 0.00 -9.16
EV to EBITDA 0.00 6.95
EV to Free Cash Flow [EV/FCF] 0.00 21.90
EV to Market Cap 0.00 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] -1.26 22.34
Price to Earnings [P/E] -3.39 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % 0.00 -27.13
Cash and Equivalents Growth (1y) % 0.00 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % 0.00 -46.93
EBITDA Growth (1y) % 0.00 -1.68
EBIT Growth (1y) % 0.00 -56.45
EBT Growth (1y) % 0.00 -12.70
EPS Growth (1y) % 0.00 -28.31
FCF Growth (1y) % 0.00 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 2.71 3.85
Current Ratio 7.87 7.27
Debt to Equity Ratio 0.00 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22